105 related articles for article (PubMed ID: 15190122)
1. In vitro internalization, intracellular transport, and clearance of an anti-CD11a antibody (Raptiva) by human T-cells.
Coffey GP; Stefanich E; Palmieri S; Eckert R; Padilla-Eagar J; Fielder PJ; Pippig S
J Pharmacol Exp Ther; 2004 Sep; 310(3):896-904. PubMed ID: 15190122
[TBL] [Abstract][Full Text] [Related]
2. Tissue distribution and receptor-mediated clearance of anti-CD11a antibody in mice.
Coffey GP; Fox JA; Pippig S; Palmieri S; Reitz B; Gonzales M; Bakshi A; Padilla-Eagar J; Fielder PJ
Drug Metab Dispos; 2005 May; 33(5):623-9. PubMed ID: 15673599
[TBL] [Abstract][Full Text] [Related]
3. The CD11a binding site of efalizumab in psoriatic skin tissue as analyzed by Multi-Epitope Ligand Cartography robot technology. Introduction of a novel biological drug-binding biochip assay.
Bonnekoh B; Böckelmann R; Pommer AJ; Malykh Y; Philipsen L; Gollnick H
Skin Pharmacol Physiol; 2007; 20(2):96-111. PubMed ID: 17167274
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of a surrogate antibody for preclinical safety testing of an anti-CD11a monoclonal antibody.
Clarke J; Leach W; Pippig S; Joshi A; Wu B; House R; Beyer J
Regul Toxicol Pharmacol; 2004 Dec; 40(3):219-26. PubMed ID: 15546677
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic-pharmacodynamic-efficacy analysis of efalizumab in patients with moderate to severe psoriasis.
Ng CM; Joshi A; Dedrick RL; Garovoy MR; Bauer RJ
Pharm Res; 2005 Jul; 22(7):1088-100. PubMed ID: 16028009
[TBL] [Abstract][Full Text] [Related]
6. Blockade of CD11a by efalizumab in psoriasis patients induces a unique state of T-cell hyporesponsiveness.
Guttman-Yassky E; Vugmeyster Y; Lowes MA; Chamian F; Kikuchi T; Kagen M; Gilleaudeau P; Lee E; Hunte B; Howell K; Dummer W; Bodary SC; Krueger JG
J Invest Dermatol; 2008 May; 128(5):1182-91. PubMed ID: 18239614
[TBL] [Abstract][Full Text] [Related]
7. Efalizumab modulates T cell function both in vivo and in vitro.
Koszik F; Stary G; Selenko-Gebauer N; Stingl G
J Dermatol Sci; 2010 Dec; 60(3):159-66. PubMed ID: 21044829
[TBL] [Abstract][Full Text] [Related]
8. The application of mechanism-based PK/PD modeling in pharmacodynamic-based dose selection of muM17, a surrogate monoclonal antibody for efalizumab.
Wu B; Joshi A; Ren S; Ng C
J Pharm Sci; 2006 Jun; 95(6):1258-68. PubMed ID: 16637054
[TBL] [Abstract][Full Text] [Related]
9. Treatment of hand and foot psoriasis with emphasis on efalizumab.
Kircik L
Skin Therapy Lett; 2007 Nov; 12(9):4-7. PubMed ID: 18087658
[TBL] [Abstract][Full Text] [Related]
10. Eruptive papules during efalizumab (anti-CD11a) therapy of psoriasis vulgaris: a case series.
Lowes MA; Chamian F; Abello MV; Leonardi C; Dummer W; Papp K; Krueger JG
BMC Dermatol; 2007 Feb; 7():2. PubMed ID: 17324275
[TBL] [Abstract][Full Text] [Related]
11. Efalizumab in the treatment of psoriasis: mode of action, clinical indications, efficacy, and safety.
Schön MP
Clin Dermatol; 2008; 26(5):509-14. PubMed ID: 18755369
[TBL] [Abstract][Full Text] [Related]
12. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody.
Gottlieb AB; Krueger JG; Wittkowski K; Dedrick R; Walicke PA; Garovoy M
Arch Dermatol; 2002 May; 138(5):591-600. PubMed ID: 12020219
[TBL] [Abstract][Full Text] [Related]
13. An overview of the pharmacokinetics and pharmacodynamics of efalizumab: a monoclonal antibody approved for use in psoriasis.
Joshi A; Bauer R; Kuebler P; White M; Leddy C; Compton P; Garovoy M; Kwon P; Walicke P; Dedrick R
J Clin Pharmacol; 2006 Jan; 46(1):10-20. PubMed ID: 16397279
[TBL] [Abstract][Full Text] [Related]
14. Efalizumab (anti-CD11a)-induced increase in peripheral blood leukocytes in psoriasis patients is preferentially mediated by altered trafficking of memory CD8+ T cells into lesional skin.
Vugmeyster Y; Kikuchi T; Lowes MA; Chamian F; Kagen M; Gilleaudeau P; Lee E; Howell K; Bodary S; Dummer W; Krueger JG
Clin Immunol; 2004 Oct; 113(1):38-46. PubMed ID: 15380528
[TBL] [Abstract][Full Text] [Related]
15. Topo-proteomic in situ analysis of psoriatic plaque under efalizumab treatment.
Bonnekoh B; Pommer AJ; Böckelmann R; Hofmeister H; Philipsen L; Gollnick H
Skin Pharmacol Physiol; 2007; 20(5):237-52. PubMed ID: 17587888
[TBL] [Abstract][Full Text] [Related]
16. Efalizumab, a reversible T-cell modulator for psoriasis.
Shear NH; Langley RG; Ho V
J Cutan Med Surg; 2006; 9 Suppl 1():4-9. PubMed ID: 16633862
[TBL] [Abstract][Full Text] [Related]
17. Effect of therapeutic integrin (CD11a) blockade with efalizumab on immune responses to model antigens in humans: results of a randomized, single blind study.
Krueger JG; Ochs HD; Patel P; Gilkerson E; Guttman-Yassky E; Dummer W
J Invest Dermatol; 2008 Nov; 128(11):2615-2624. PubMed ID: 18496564
[TBL] [Abstract][Full Text] [Related]
18. Efalizumab-induced autoimmune pancytopenia.
Tom WL; Miller MD; Hurley MY; Suneja T; Kudva G; Leonardi CL; Obadiah JM
Br J Dermatol; 2006 Nov; 155(5):1045-7. PubMed ID: 17034539
[TBL] [Abstract][Full Text] [Related]
19. Profiling lymphocyte subpopulations in peripheral blood under efalizumab treatment of psoriasis by multi epitope ligand cartography (MELC) robot microscopy.
Bonnekoh B; Malykh Y; Böckelmann R; Bartsch S; Pommer AJ; Gollnick H
Eur J Dermatol; 2006; 16(6):623-35. PubMed ID: 17229602
[TBL] [Abstract][Full Text] [Related]
20. CLinical experience acquired with the efalizumab (Raptiva) (CLEAR) trial in patients with moderate-to-severe plaque psoriasis: results from a phase III international randomized, placebo-controlled trial.
Dubertret L; Sterry W; Bos JD; Chimenti S; Shumack S; Larsen CG; Shear NH; Papp KA;
Br J Dermatol; 2006 Jul; 155(1):170-81. PubMed ID: 16792770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
